CD47 and cancer: In several cancer models, inhibition of the CD47-SIRP signaling axis with anti-CD47 antibodies or engineered SIRP-Fc fusions have been shown to restore the ability of macrophages to phagocytose cancer cells and to stimulate cytotoxic CD8+ T cell responses, thereby inhibiting the malignant progression of tumors [63, 64].